Chugai’s PNH Med, Takeda’s cTTP Therapy Up for Advisory Panel Review on Feb. 29

A key health ministry advisory panel will discuss on February 29 whether to endorse approval for a batch of new medicines including Chugai Pharmaceutical’s anti-C5 recycling monoclonal antibody crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Crovalimab is one...read more